A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans


Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.

Aim(s): We hypothesized that chronic PPI use would increase circulating plasma gastrin, CGA and pancreastatin levels.

Materials and methods: Thirty patients who used PPIs for six months or more (mean duration 3.1 ±2.5 years) and a separate control group of thirty patients who never used antacid medications were prospectively evaluated with plasma gastrin, CGA and pancreastatin determinations.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Raines D, Chester M, Diebold A, Mamikunian P, Anthony C,

Keywords: Chromogranin A, gastrin, pancreastatin, neuroendocrine tumor (NET),

To read the full abstract, please log into your ENETS Member account.